ESC Premium Access

PCSK9i, changing practice in cardiology: the emerging story

Event: ESC CONGRESS 2019
Topic: Risk Factors and Prevention
Session type: Satellite Symposium
Organised by PACE-CME, supported with an educational grant provided by Amgen, Draupnir Bio ApS, Sanofi-Regeneron & The Medicines Company
Date: 31 August 2019
Time: 15:30 - 16:30

Congress Session

5 presentations in this session

Introduction

Speaker: Professor J. Chapman (Paris, FR)
Thumbnail

Insights and lessons from the ODYSSEY outcomes trial: which patients benefit most?

Speaker: Professor P. Steg (Paris, FR)
Thumbnail

Extending the evidence: what did the FOURIER trial learns us on managing high risk patients?

Speaker: Professor M. Sabatine (Boston, US)
Thumbnail

Targeting PCSK9: expanding knowledge and targeting new frontiers

Speaker: Professor J. Kastelein (Amsterdam, NL)
Thumbnail

Discussion

Speaker: Professor J. Chapman (Paris, FR)
Speaker: Professor J. Kastelein (Amsterdam, NL)
Thumbnail

6 speakers from this session

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)
47 presentations
2 followers

Professor Marc Sabatine

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
16 presentations
0 follower

Professor John Kastelein

Faculty of Medecine - University of Amsterdam, Amsterdam (Netherlands (The))
21 presentations
1 follower

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

Professor John Kastelein

Faculty of Medecine - University of Amsterdam, Amsterdam (Netherlands (The))
21 presentations
1 follower

This platform is supported by

logo Novo Nordisk